Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

por Lewis, James H., Khaldoyanidi, Sophia K., Britten, Carolyn D., Wei, Andrew H., Subklewe, Marion
Publicado 2022

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

por Britten, Carolyn D, Gomes, Antoinette S, Wainberg, Zev A, Elashoff, David, Amado, Rafael, Xin, Yan, Busuttil, Ronald W, Slamon, Dennis J, Finn, Richard S
Publicado 2012

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

por von Mehren, Margaret, Britten, Carolyn D., Pieslor, Peter, Saville, Wayne, Vassos, Artemios, Harris, Sarah, Galluppi, Gerald R., Darif, Mohamed, Wainberg, Zev A., Cohen, Roger B., Leong, Stephen
Publicado 2014

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

por Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep
Publicado 2017

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of meta...

por Noel, Marcus, O’Reilly, Eileen M., Wolpin, Brian M., Ryan, David P., Bullock, Andrea J., Britten, Carolyn D., Linehan, David C., Belt, Brian A., Gamelin, Eric C., Ganguly, Bishu, Yin, Donghua, Joh, Tenshang, Jacobs, Ira A., Taylor, Carrie T., Lowery, Maeve A.
Publicado 2019

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

por Mehrotra, Shikhar, Britten, Carolyn D., Chin, Steve, Garrett-Mayer, Elizabeth, Cloud, Colleen A., Li, Mingli, Scurti, Gina, Salem, Mohamed L., Nelson, Michelle H., Thomas, Melanie B., Paulos, Chrystal M., Salazar, Andres M., Nishimura, Michael I., Rubinstein, Mark P., Li, Zihai, Cole, David J.
Publicado 2017

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

por Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C., Safran, Howard, Stinchcombe, Thomas E., Srdanov, Marko, Gelb, Arnold B., Schlichting, Michael, Chin, Kevin, Gulley, James L.
Publicado 2017

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

por Stewart, Mark D., McCall, Bruce, Pasquini, Marcelo, Yang, Allen S., Britten, Carolyn D., Chuk, Meredith, De Claro, R Angelo, George, Bindu, Gormley, Nicole, Horowitz, Mary M., Kowack, Eric, McCoy, Candice, Morrow, Phuong Khanh, Okoye, Emmanuel, Ricafort, Rosanna, Rossi, John, Sharon, Elad, Theoret, Marc, Vegni, Ferdinando, Yu, Tai, Allen, Jeff
Publicado 2022